It is essential that, as the UK’s leading breast cancer charity, we engage with the key stakeholders that will be central to helping stop women dying from the disease. The pharmaceutical industry has a crucial role to play in achieving this vision – and collaborating with the industry is something we know our supporters understand and want us to do. 

Organisational pharmaceutical policy

We are open and transparent about our partnerships with the industry. We have agreements in place for each partnership and our work with pharmaceutical companies is underpinned by an organisational pharmaceutical policy. This policy provides clear guidance on how we partner with pharmaceutical and other life sciences companies, including the limits we place on donations as a percentage of our annual income and that we have no preference for working with any one company, and welcome funding from multiple companies where practical and appropriate.  

We do not accept specific funding for our policy and campaigns work or use pharmaceutical donations to fund our policy and campaigns work. Where necessary, we will campaign against pharmaceutical companies on issues regarding access to drugs, in the interests of breast cancer patients, regardless of whether Breast Cancer Now is currently receiving funding or has historically received funding from a specific company. 

This policy was agreed in 2022 and will next be reviewed in 2023.

During our 2021/22 financial year, donations from these organisations, amounted to £388,320. We thank the following companies for their support: 

  1. Daiichi Sankyo Ltd
  2. Eli Lilly and Company Ltd
  3. Novartis 
  4. Pfizer
  5. Roche Products Ltd

Support included grants towards our Living with Secondary Breast Cancer support services and Service Pledge.